Tìm theo
NX-1207
Thuốc Gốc
Small Molecule
NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).
Dược Lực Học : NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. BPH is a common disorder of older men, afflicting approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.
Cơ Chế Tác Dụng : NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH). NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed.
Độc Tính : The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. In particular, patients given NX-1207 had no (0%) significant sexual side effects
Chỉ Định : Investigated for use/treatment in benign prostatic hyperplasia.
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB05493
... loading
... loading